SCHEMBL10791978

SCHEMBL10791978

Cc1c(F)c(=O)oc2cc(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 7/20 1.00
ESR1 P03372 4/20 0.60
ESR2 Q92731 4/20 0.60
ERAP1 Q9NZ08 2/20 0.60
PDE2A O00408 1/20 0.57
KDM4E B2RXH2 4/20 0.56
GLA P06280 4/20 0.56
GAA P10253 4/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
CASP1 P29466 3/20 0.56
CASP7 P55210 3/20 0.56
HSD17B10 Q99714 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
TSHR P16473 1/20 0.56
NPC1 O15118 1/20 0.55
CCR4 P51679 1/20 0.55
CA12 O43570 1/20 0.54
LMNA P02545 1/20 0.54
CYP1A2 P05177 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30675224 1.00 HSD17B3 (1.00) HSD17B3ESR1ESR2ERAP1PDE2A
Phosphoric Acid SCHEMBL27762580 0.94 HSD17B3 (0.88) HSD17B3ESR1ESR2ERAP1PDE2A
SCHEMBL10792491 0.87 HSD17B3 (0.77) HSD17B3ESR1ESR2ERAP1PDE2A
SCHEMBL10791381 0.87 HSD17B3 (0.77) HSD17B3ESR1ESR2ERAP1PDE2A
SCHEMBL31366988 0.86 HSD17B3 (1.00) HSD17B3ESR1ESR2ERAP1PDE2A
SCHEMBL591899 0.86 HSD17B3 (1.00) HSD17B3ESR1ESR2ERAP1PDE2A
SCHEMBL28446883 0.84 HSD17B3 (0.96) HSD17B3ESR1ESR2ERAP1PDE2A
SCHEMBL609585 0.84 HSD17B3 (0.73) HSD17B3ESR1ESR2PDE2AKDM4E
SCHEMBL6907581 0.80 HSD17B3 (0.75) HSD17B3ESR1ESR2ERAP1PDE2A
SCHEMBL1024770 0.80 HSD17B3 (1.00) HSD17B3ESR1ESR2ERAP1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1612939-A Method for highly sensitive and continuous detection of Protein Tyrosine Phosphatase (PTP) using 6, 8-difluoro-4-methyl-7-hydroxycoumarin phosphate AVENTIS PHARMA GMBH (DE) 2005-05-04 CN claimed
US-20240117092-A1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2024-04-11 US disclosed
EP-4284787-A1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-12-06 EP disclosed
CN-112961205-B Preparation method and medical application of sulfonamide compounds with coumarin and glycosyl structures 沈阳药科大学 2022-10-14 CN disclosed
EP-4036085-A1 COMPOUNDS FOR OPTICALLY ACTIVE OPHTHALMIC DEVICES AMO Ireland (IE) 2022-08-03 EP disclosed
CN-112961205-A Preparation method and medical application of sulfonamide compounds with coumarin and glycosyl structures 沈阳药科大学 2021-06-15 CN disclosed
CN-105566269-A Preparation and pharmacological effects of coumarin derivative and application of coumarin derivative to treatment on pruritus UNIV BEIJING 2016-05-11 CN disclosed
CN-105524034-A Preparation method of coumarin derivative, pharmacological effect of coumarin derivative and use of coumarin derivative in treatment on cerebral ischemia UNIV BEIJING 2016-04-27 CN disclosed
CN-102459303-A Phytases, nucleic acids encoding them and methods of making and using them VERENIUM CORP 2012-05-16 CN disclosed
CN-102317296-A Fused aromatic PTP-1B inhibitors MERCK FROSST CANADA LTD 2012-01-11 CN disclosed
CN-102137936-A Particles for detecting intracellular targets UNIV NORTHWESTERN 2011-07-27 CN disclosed
CN-102076847-A Rna polyphosphatase compositions, kits, and uses thereof EPICT TECHNOLOGIES CORP 2011-05-25 CN disclosed
CN-102076851-A Selective 5' ligation tagging of rna EPICT TECHNOLOGIES CORP 2011-05-25 CN disclosed
CN-101282719-A Glepp-1 inhibitors for the treatment of autoimmune and/or inflammatory diseases SERONO LAB (CH) 2008-10-08 CN disclosed
CN-1665790-A Compositions and methods for detection and isolation of phosphorylated molecules MOLECULAR PROBES INC (US) 2005-09-07 CN disclosed
CN-1612939-A Method for highly sensitive and continuous detection of Protein Tyrosine Phosphatase (PTP) using 6, 8-difluoro-4-methyl-7-hydroxycoumarin phosphate AVENTIS PHARMA GMBH (DE) 2005-05-04 CN disclosed
EP-0111746-B1 SULFONIC-ACID ESTERS OF HYDROXYCOUMARINES, THEIR PREPARATION AND MEDICINES CONTAINING THEM BASF Aktiengesellschaft (DE) 1987-09-16 EP disclosed
US-4618622-A ANTIDEPRESSANTS, ANTIALLERGENS BASF AKTIENGESELLSCHAFT (DE) 1986-10-21 US disclosed
EP-0111746-A2 Sulfonic-acid esters of hydroxycoumarines, their preparation and medicines containing them BASF Aktiengesellschaft (DE) 1984-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240117092-A1 OPTICALLY ACTIVE DEVICES PDE6C, UACA, PDE6A HSD17B3 3080/4885ESR1 3856/4885ESR2 4636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.